Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044655
Status:
COMPLETED
Last Update Posted:
2016-04-28
First Post:
2002-09-03
Brief Title:
Switching Medication to Treat Schizophrenia
Sponsor:
Icahn School of Medicine at Mount Sinai
Organization:
Icahn School of Medicine at Mount Sinai
Study Overview
Official Title:
Effectiveness of Switching Antipsychotic Medications
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia
Detailed Description:
Over the past several years new atypical antipsychotic medications have become available to treat schizophrenia with little information to guide prescribing for relatively stable outpatients
Participants will be randomly assigned to either continue taking their current medications for schizophrenia or to switch to a new medication Participants assigned to switch to a new medication will begin receiving either olanzapine Zyprexa risperidone Risperdal ziprasidone Geodon quetiapine Seroquel or aripiprazole Abilify depending on what they are currently taking Participants currently taking a single oral medication will switch to olanzapine risperidone ziprasidone quetiapine or aripiprazole Participants currently taking a single conventional injectable will begin taking long-acting injectable risperidone Risperdal Consta Participants currently taking two antipsychotic medications will begin taking only one of the medications they are currently using Participants will stay on their assigned treatment for 6 months after which time the participants prescribing psychiatrist will advise the participant on which medication should be used Study participants are interviewed at study start and at follow-up visits for 1 year
Participants will be randomly assigned to either continue taking their current medications for schizophrenia or to switch to a new medication Participants assigned to switch to a new medication will begin receiving either olanzapine Zyprexa risperidone Risperdal ziprasidone Geodon quetiapine Seroquel or aripiprazole Abilify depending on what they are currently taking Participants currently taking a single oral medication will switch to olanzapine risperidone ziprasidone quetiapine or aripiprazole Participants currently taking a single conventional injectable will begin taking long-acting injectable risperidone Risperdal Consta Participants currently taking two antipsychotic medications will begin taking only one of the medications they are currently using Participants will stay on their assigned treatment for 6 months after which time the participants prescribing psychiatrist will advise the participant on which medication should be used Study participants are interviewed at study start and at follow-up visits for 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MH059312 | NIH | None | httpsreporternihgovquickSearchR01MH059312 |